Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P56696
UPID:
KCNQ4_HUMAN
Alternative names:
KQT-like 4; Potassium channel subunit alpha KvLQT4; Voltage-gated potassium channel subunit Kv7.4
Alternative UPACC:
P56696; O96025
Background:
Potassium voltage-gated channel subfamily KQT member 4 (Kv7.4) plays a crucial role in regulating neuronal excitability. It is implicated in the modulation of sensory cells in the cochlea, suggesting its importance in auditory functions. Kv7.4 channels are sensitive to various pharmacological agents, including linopirdine and XE991.
Therapeutic significance:
Kv7.4's involvement in autosomal dominant deafness, 2A highlights its potential as a therapeutic target. Understanding its role could pave the way for innovative treatments for sensorineural hearing loss, offering hope for affected individuals.